Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19209926 | 0.90 | MEN1 (0.34) | MEN1KMT2ATSHRHCAR2 | |
| SCHEMBL6059540 | 0.74 | ALDH1A1 (0.37) | MEN1KMT2ATSHR | |
| SCHEMBL28145028 | 0.71 | TSHR (0.40) | MEN1KMT2ATSHRHCAR2 | |
| SCHEMBL20564587 | 0.69 | TSHR (0.48) | MEN1KMT2ATSHRHCAR2HTT | |
| SCHEMBL622786 | 0.69 | TSHR (0.42) | MEN1KMT2ATSHRHCAR2HTT | |
| SCHEMBL2098739 | 0.69 | TSHR (0.42) | MEN1KMT2ATSHRHCAR2HTT | |
| SCHEMBL448528 | 0.67 | TSHR (0.46) | MEN1KMT2ATSHRHCAR2HTT | |
| SCHEMBL2244400 | 0.67 | MEN1 (0.37) | MEN1KMT2ATSHRHCAR2 | |
| SCHEMBL2246646 | 0.67 | MEN1 (0.37) | MEN1KMT2ATSHRHCAR2 | |
| SCHEMBL11419549 | 0.66 | ALDH1A1 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | MEN1 2759/4885KMT2A 1120/4885TSHR 2497/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | MEN1 2668/4885KMT2A 1125/4885TSHR 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.